A Recommendation Is Not a Duty.
In India, a DGTR finding is only a recommendation. The Finance Ministry decides whether it becomes a duty, and the record on that step has moved sharply.
Read MoreResearch library
Blogs
Perspectives on emerging signals, methods and market changes.
6 resources · Page 1 of 1
First to file is not first to launch: the Entyvio race
Three vedolizumab biosimilar applications have been announced as accepted for FDA review. Why the order of announcements does not decide who sells first.
Read MoreOne Company, Two Anticoagulants, Two Different Records
Aurobindo holds FDA approvals for generic rivaroxaban and apixaban. One has a US product listed for sale and the other does not. What each record shows.
Read MorePhenol and Acetone: One Price Problem
Phenol and acetone come out of one reactor. Customs data from India and Europe shows acetone's import value rose twice as fast as phenol's in 2026.
Read MoreWestlake Did Not Blame the BPA Ban for Closing Pernis. The Record Cannot Say More.
Westlake's filing gives its European business, not the EU BPA ban, as the reason to close Pernis. What the dates and import data can and cannot show.
Read MoreWhat MSN’s Entresto Court Win Did and Did Not Decide
In July 2025 a US court held Novartis had not proved MSN infringed one Entresto patent. The FDA register lists ten generic applications dated before that.
Read MoreNo resources match these filters. Try another topic or search.